Established in 1994, the Medicines Evaluation Unit is primarily owned by the North West Lung Centre charity. All profits benefit pioneering academic respiratory research. It is however, a fully commercial CRO.

The MEU’s core skill area is in early phase exploratory healthy volunteer trials in numerous indications. Our respiratory trials involve asthma, COPD, cough, IPF, and cystic fibrosis. Our bespoke, phenotyped database holds approximately 17,000 volunteers with respiratory conditions.

Over 470 studies have been completed since 1994. The site’s hard work has been formally recognized with multiple awards such as “Winner of Clinical Trial Research Team of the Year “ at the GCP Clinical Excellence awards, and the Queen’s Award for Enterprise.

It is home to internationally recognized investigators such as Professor Dave Singh (Asthma/COPD), and Professor Ashley Woodcock, the co-chair for the Montreal Protocol on the phasing out of ozone depleting substances (ODS).

The MEU has already carried out several non-CFC propellant clinical studies for Chiesi and GSK. All studies were accelerated through the site to timescale, and under budget thanks to our respiratory experience, facilities, and bespoke volunteer database of over 40,000 pre-screened individuals.